Cardiovascular hypertrophy: Role of angiotensin II and bradykinin

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 2, 1996, Pages

  Waeber, Bernard ^a   Brunner, Hans R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin II antagonist; Bradykinin antagonist; Endothelium; Kallikrein kinin system; Neointimal proliferation; Renin angiotensin system; Vascular and cardiac hypertrophy

Indexed keywords

ANGIOTENSIN; BRADYKININ;

ARTERY INTIMA PROLIFERATION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RESPONSE; CONFERENCE PAPER; DRUG EFFECT; ENDOTHELIUM INJURY; ENZYME INHIBITION; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; KALLIKREIN KININ SYSTEM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR SMOOTH MUSCLE;

EID: 0029917129     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199600002-00008     Document Type: Conference Paper

References (37)

1. Oparil S, Haber E. The renin-angiotensin system. N Engl J Med 1974;291:389-401.
2. Carretero OA, Scicli AG. Local hormonal factors (intacrine, autocrine, and paracrine) in hypertension. Hypertension 1991;18(suppl I):58-69.
3. Erdös EG. Angiotensin I converting enzyme. Circ Res 1975; 36:247-55.
4. Lever AF, Lyall F, Morton JJ, Folkow B. Angiotensin II, vascular structure and blood pressure. Kidney Int 1992; 41(suppl 37):51-5.
5. Kent RL, Mann DL, Cooper G. Signals for cardiac muscle hypertrophy in hypertension. J Cardiovasc Pharmacol 1991; 17(suppl 2):7-13.
6. Freslon JL, Giudicelli JF. Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats. Br J Pharmacol 1983;80:533-43.
7. Clozel JP, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989;7:267-75.
8. Clozel JP, Kuhn H, Hefti F. Decreases of vascular hypertrophy in four different types of arteries in spontaneously hypertensive rats. Am J Med 1989;87(suppl 6B):93-5.
9. Linz W, Schölkens BA. Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens [A] A11:1325-50.
10. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994;23:83-91.
11. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
12. Powell JS, Clozel JP, Müller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.
13. Azuma H, Niimi Y, Hamasaki H. Prevention of intimai thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. Br J Pharmacol 1992;106: 665-71.
14. Taguchi J, Abe J, Ohno M, Schwartz SM, Kurokawa K. Topical application of AT1 receptor antagonists prevents medial and neointimal proliferation after balloon injury. Blood Pressure 1994;3(suppl 5):38-42.
15. Kino H, Hama J, Takenaka T, et al. Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury. Blood Pressure 1994; 3(suppl 5):43-8.
16. Mombouli JV, Vanhoutte PM. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 1992;20(suppl 9): S74-83.
17. Schör K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992;20(suppl 9):S68-73.
18. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
19. Shirotani P, Yui Y, Hattori R, Kawai C. U-61431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins 1991;41:97-110.
20. Timmermans BMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
21. Niederberger M, Aubert JF, Nussberger J, Brunner HR, Waeber B. Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist. J Hypertens 1995;13:439-45.
22. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 1986;8: 971-4.
23. Carbonell LF, Carretero OA, Stewart JM, Scicli AG. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988;11: 239-43.
24. Waeber B, Juillerat-Jeanneret L, Aubert JF, Schapira M, Nussberger J, Brunner HR. Involvement of the kallikreinkinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors. Br J din Pharmacol 1989;27: 175S-80S.
25. Bao G, Gohlke P, Unger T. Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. J Cardiovasc Pharmacol 1992;20(suppl 9):96-9.
26. Seyedi N, Xu XB, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70.
27. Griffin SA, Brown WCB, MacPherson F, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17:626-35.
28. Jespersen LT, Nyborg NCB, Pedersen OL, Mikkelsen EO, Mulvany MJ. Cardiac mass and peripheral vascular structure in hydralazine-treated spontaneously hypertensive rats. Hypertension 1985;7:734-41.
29. Nyborg NCB, Mulvany MJ. Lack of effect of antihypertensive treatment with felodipine on cardiovascular structure of young spontaneously hypertensive rats. Cardiovasc Res 1985;19:528-36.
30. Jespersen LT, Baandurp U, Nyborg NCB, Mikkelsen EO, Lederballe O. Aggressive long-term antihypertensive therapy with pinacidil does not cause regression of cardiovascular hypertrophy in the spontaneously hypertensive rat. J Hypertens 1986;4:223-7.
31. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987;9:178-87.
32. Morton JJ, Beattie EC, MacPherson F. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J Vasc Res 1992;29:264-9.
33. Farhy RD, Ho KL, Carretero OA, Scicli AG. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992;182:283-8.
34. Farhy RD, Carretero AA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993;72: 1202-10.
35. Janiak P, Pillon A, Prost JF, Vilaine JP. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992;20:737-45.
36. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83:1771-9.
37. Linz W, Schölkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-2.